These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 25801797

  • 1. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
    Hughes DA, Gonzalez DE, Lukina EA, Mehta A, Kabra M, Elstein D, Kisinovsky I, Giraldo P, Bavdekar A, Hangartner TN, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 3. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D.
    Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
    [Abstract] [Full Text] [Related]

  • 4. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 5. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 6. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 15; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 8. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 15; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 9. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D.
    Blood; 2010 Jun 10; 115(23):4651-6. PubMed ID: 20299511
    [Abstract] [Full Text] [Related]

  • 10. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
    Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A.
    Blood Cells Mol Dis; 2015 Dec 10; 55(4):415-8. PubMed ID: 26460268
    [Abstract] [Full Text] [Related]

  • 11. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D.
    Genet Med; 2014 May 10; 16(5):359-66. PubMed ID: 24263462
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
    Ida H, Tanaka A, Matsubayashi T, Murayama K, Hongo T, Lee HM, Mellgard B.
    Blood Cells Mol Dis; 2016 Jul 10; 59():140-7. PubMed ID: 27241455
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA.
    Am J Hematol; 2013 Mar 10; 88(3):172-8. PubMed ID: 23339116
    [Abstract] [Full Text] [Related]

  • 14. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 15. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
    Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A.
    Mol Genet Metab; 2017 Mar 27; 120(1-2):111-115. PubMed ID: 27614581
    [Abstract] [Full Text] [Related]

  • 16. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AA, Qin Y, Qiu Y, Dinh Q, Zimran A.
    Blood Cells Mol Dis; 2016 Jul 27; 59():37-43. PubMed ID: 27282565
    [Abstract] [Full Text] [Related]

  • 17. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.
    J Immunol Methods; 2011 Oct 28; 373(1-2):45-53. PubMed ID: 21846471
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
    Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J.
    Orphanet J Rare Dis; 2021 Dec 04; 16(1):502. PubMed ID: 34863216
    [Abstract] [Full Text] [Related]

  • 19. Velaglucerase alfa: a new option for Gaucher disease treatment.
    Zimran A.
    Drugs Today (Barc); 2011 Jul 04; 47(7):515-29. PubMed ID: 22013559
    [Abstract] [Full Text] [Related]

  • 20. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, Turkia HB.
    Blood Cells Mol Dis; 2018 Feb 04; 68():153-159. PubMed ID: 27839979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.